Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Deferred Tax (2023 - 2025)

Ascendis Pharma A (ASND) has disclosed Long-Term Deferred Tax for 3 consecutive years, with -$11.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 44.43% to -$11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$11.2 million through Dec 2025, down 44.43% year-over-year, with the annual reading at -$11.2 million for FY2025, 44.43% down from the prior year.
  • Long-Term Deferred Tax hit -$11.2 million in Q4 2025 for Ascendis Pharma A, down from -$7.8 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of -$6.3 million in Q4 2023 to a low of -$11.2 million in Q4 2025.
  • Historically, Long-Term Deferred Tax has averaged -$8.4 million across 3 years, with a median of -$7.8 million in 2024.
  • Biggest five-year swings in Long-Term Deferred Tax: decreased 23.64% in 2024 and later plummeted 44.43% in 2025.
  • Year by year, Long-Term Deferred Tax stood at -$6.3 million in 2023, then fell by 23.64% to -$7.8 million in 2024, then plummeted by 44.43% to -$11.2 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for ASND at -$11.2 million in Q4 2025, -$7.8 million in Q4 2024, and -$6.3 million in Q4 2023.